ATE541053T1 - Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs - Google Patents

Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs

Info

Publication number
ATE541053T1
ATE541053T1 AT06022167T AT06022167T ATE541053T1 AT E541053 T1 ATE541053 T1 AT E541053T1 AT 06022167 T AT06022167 T AT 06022167T AT 06022167 T AT06022167 T AT 06022167T AT E541053 T1 ATE541053 T1 AT E541053T1
Authority
AT
Austria
Prior art keywords
lung cancer
small cell
cell lung
methods
compositions
Prior art date
Application number
AT06022167T
Other languages
English (en)
Inventor
Yusuke Nakamura
Yataro Daigo
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE541053T1 publication Critical patent/ATE541053T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
AT06022167T 2002-09-30 2003-09-22 Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs ATE541053T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41467302P 2002-09-30 2002-09-30
US45137403P 2003-02-28 2003-02-28
US46610003P 2003-04-28 2003-04-28

Publications (1)

Publication Number Publication Date
ATE541053T1 true ATE541053T1 (de) 2012-01-15

Family

ID=32074369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06022167T ATE541053T1 (de) 2002-09-30 2003-09-22 Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs

Country Status (8)

Country Link
EP (30) EP2270216A3 (de)
JP (4) JP4425141B2 (de)
KR (2) KR20110020953A (de)
AT (1) ATE541053T1 (de)
AU (1) AU2003272088A1 (de)
CA (1) CA2500151A1 (de)
TW (1) TW200413725A (de)
WO (1) WO2004031413A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300469A (en) * 1992-12-08 1994-04-05 Engelhard Corporation Composition for passivating vanadium in catalytic cracking and preparation thereof
US8048629B2 (en) * 1996-03-15 2011-11-01 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
WO2004016758A2 (en) * 2002-08-15 2004-02-26 Genzyme Corporation Brain endothelial cell expression patterns
EP2462936A1 (de) * 2003-01-03 2012-06-13 Gencia Corporation SiRNA-vermitteltes posttranskriptionelles Gen-Silencing von Alopecia-Genen
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1730533A1 (de) * 2004-03-24 2006-12-13 Oncotherapy Science, Inc. Adam8 als tumormarker und therapeutisches target von nichtkleinzelligem lungenkrebs
EP2336778A1 (de) * 2004-03-24 2011-06-22 Oncotherapy Science, Inc. Zusammensetzungen und Verfahren zur Behandlung von Lungenkrebs
WO2006016697A1 (en) * 2004-08-10 2006-02-16 Oncotherapy Science, Inc. Non-small cell lung cancer-related gene, anln, and its interactions with rhoa
CN101068935B (zh) * 2004-08-10 2012-06-27 肿瘤疗法科学股份有限公司 与乳腺癌相关的基因和多肽
WO2006033460A1 (en) * 2004-09-24 2006-03-30 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers by trna-dihydrouridine synthase activity of urlc8
US8034578B2 (en) 2004-10-19 2011-10-11 Oncotherapy Science, Inc. PKP3 oncogene as a prognostic indicator for lung cancer
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
JP2008523816A (ja) * 2004-12-15 2008-07-10 ベス イスラエル ディーコネス メディカル センター 妊娠合併症の診断および処置に有用な核酸およびポリペプチド
WO2006085684A2 (en) * 2005-02-10 2006-08-17 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
DE602006021283D1 (de) 2005-02-25 2011-05-26 Oncotherapy Science Inc Peptid-impfstoff für lungenkrebs, der ttk polypeptide exprimiert
WO2006093337A1 (ja) * 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
WO2006105642A1 (en) * 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
JP2008539693A (ja) * 2005-05-12 2008-11-20 オンコセラピー・サイエンス株式会社 抗ｄｓｃ２抗体のエフェクター機能を用いて細胞を障害する方法
ES2379805T3 (es) 2005-07-27 2012-05-03 Oncotherapy Science, Inc. ECT2 como diana terapéutica del cáncer de esófago
DE102005052384B4 (de) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
KR100759288B1 (ko) * 2005-11-14 2007-09-17 가톨릭대학교 산학협력단 비교유전자보합법을 이용한 폐암 및 폐암의 하부유형 진단방법
JP5321780B2 (ja) 2006-02-10 2013-10-23 オンコセラピー・サイエンス株式会社 肺癌の治療方法
US20090311685A1 (en) * 2006-04-20 2009-12-17 Oncotherapy Science, Inc NMU-GHSR1b/NTSR1 oncogenic signaling pathway as a therapeutic target for lung cancer
EP2049905B1 (de) * 2006-08-01 2010-05-19 Roche Diagnostics GmbH Verwendung von nnmt als marker für lungenkrebs
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
WO2008020653A1 (en) * 2006-08-18 2008-02-21 Oncotherapy Science, Inc. Use of holliday junction-recognizing protein related to cancer
WO2008020652A1 (en) * 2006-08-18 2008-02-21 Oncotherapy Science, Inc. Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer
EP2423332A1 (de) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognosemarker und therapeutische Targets für Lungenkrebs
US20080145313A1 (en) * 2006-08-30 2008-06-19 Genesis Research & Development Corporation Limited Compositions and Methods for the Treatment and Prevention of Neoplastic Disorders
CA2915560A1 (en) 2006-10-17 2008-04-24 Tomoaki Fujioka Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
WO2008072777A2 (en) 2006-12-13 2008-06-19 Oncotherapy Science, Inc. Ttk as tumor marker and therapeutic target for lung cancer
KR100846354B1 (ko) * 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
JP2010523081A (ja) * 2007-03-30 2010-07-15 オンコセラピー・サイエンス株式会社 Ｃｄｃａ８−ａｕｒｋｂ複合体を標的とするスクリーニング方法およびｎｓｃｌｃの治療方法
US8822153B2 (en) 2007-06-01 2014-09-02 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
US20100291091A1 (en) * 2007-07-30 2010-11-18 ONCOTHERAPY SCIENCE ,inc. Cancer associated gene ly6k
AU2008290060B2 (en) 2007-08-20 2014-04-24 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
KR101543624B1 (ko) 2007-08-20 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｆｏｘｍ１ 펩티드 및 이를 포함하는 약학적 조성물
WO2009025117A1 (ja) * 2007-08-20 2009-02-26 Oncotherapy Science, Inc. Cdca1ペプチド及びこれを含む薬剤
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
CN104109208A (zh) 2007-11-14 2014-10-22 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
JP5593560B2 (ja) 2008-06-30 2014-09-24 オンコセラピー・サイエンス株式会社 放射性同位体標識で標識された抗ｃｄｈ３抗体およびその使用
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI580431B (zh) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
EP2334790A1 (de) * 2008-08-27 2011-06-22 Oncotherapy Science, Inc. Gen ttll4 in verbindung mit pankreaskarzinom
JP2012501166A (ja) * 2008-08-27 2012-01-19 オンコセラピー・サイエンス株式会社 乳癌関連遺伝子ｒｑｃｄ１
RU2011111411A (ru) * 2008-08-28 2012-10-10 Онкотерапи Сайенс, Инк. (Jp) Oip5 в качестве гена-мишени для терапии и диагностики рака
KR101064561B1 (ko) * 2008-09-24 2011-09-14 고려대학교 산학협력단 폐선암 수술 후 초기 재발 예측용 바이오마커
US20110301056A1 (en) * 2008-12-12 2011-12-08 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
EP3257953B1 (de) 2009-03-12 2018-09-26 Cancer Prevention And Cure, Ltd. Verfahren zur identifizierung, beurteilung, prävention und behandlung von lungenerkrankungen sowie kits dafür mit geschlechtsspezifischer krankheitsidentifizierung, beurteilung, prävention und behandlung
TW201102081A (en) 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
KR101757798B1 (ko) 2009-09-03 2017-07-14 도레이 카부시키가이샤 면역 유도제
JP5728718B2 (ja) 2009-12-28 2015-06-03 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体およびその使用
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
SG10201501857YA (en) 2010-03-11 2015-05-28 Oncotherapy Science Inc Hjurp Peptides And Vaccines Including The Same
WO2011129427A1 (ja) * 2010-04-16 2011-10-20 第一三共株式会社 癌の診断剤および治療剤
JP5849303B2 (ja) 2010-07-30 2016-01-27 オンコセラピー・サイエンス株式会社 キノリン誘導体および同一物を含むｍｅｌｋ阻害剤
US8933050B2 (en) 2010-09-02 2015-01-13 Institute National De La Sante Et De La Recherche Medicale (Inserm) Methods for the treatment and the diagnosis of cancer
CN103703371A (zh) * 2011-04-29 2014-04-02 癌症预防和治疗有限公司 使用分类***及其试剂盒识别和诊断肺部疾病的方法
WO2012153492A1 (en) * 2011-05-06 2012-11-15 Oncotherapy Science, Inc. Nptx2 as tumor marker and therapeutic target for cancer
WO2012157239A1 (en) * 2011-05-16 2012-11-22 Oncotherapy Science, Inc. Chodl as tumor marker and therapeutic target for cancer
BR112014001363B1 (pt) 2011-08-12 2021-06-01 Oncotherapy Science, Inc. Composições para indução de um linfócito t citotóxico (ctl), para indução de uma célula apresentadora de antígeno (apc) tendo capacidade de indução de ctl, composição farmacêutica, métodos in vitro para indução de apc e de ctl, usos de peptídeos e vetor
US9926604B2 (en) 2011-10-14 2018-03-27 The Regents Of The University Of California Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same
AU2012366148B2 (en) 2012-01-19 2016-12-01 Oncotherapy Science, Inc. 1,5-naphthyridine derivatives and melk inhibitors containing the same
KR101308924B1 (ko) * 2012-02-21 2013-09-23 차의과학대학교 산학협력단 신규한 ｍｉＲＮＡ ｈｃ－ｓｍＲ－Ｓ２－５ 및 이의 용도
CN104168917A (zh) 2012-03-09 2014-11-26 肿瘤疗法科学股份有限公司 含有肽的医药组合物
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
US9644010B2 (en) 2012-07-10 2017-05-09 Oncotherapy Science, Inc. LY6K epitope peptides for TH1 cells and vaccines containing the same
JP6255593B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン
GB201213229D0 (en) * 2012-07-25 2012-09-05 Isis Innovation Assay
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR101447901B1 (ko) 2013-04-16 2014-10-16 한양대학교 산학협력단 지방세포 표적 비바이러스성 유전자 전달체
TWI643867B (zh) 2013-05-24 2018-12-11 日商腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗
CN107208131A (zh) 2014-05-30 2017-09-26 基因中心治疗公司 用于肺癌分型的方法
SG10201900835XA (en) 2014-08-04 2019-03-28 Oncotherapy Science Inc Urlc10-derived peptide and vaccine containing same
EP3981416B1 (de) 2014-08-04 2024-03-20 OncoTherapy Science, Inc. Koc1-abgeleitetes peptid und impfstoff damit
JPWO2016121715A1 (ja) * 2015-01-26 2017-11-02 国立大学法人名古屋大学 肺がん患者の予後を評価するための情報を提供する方法、肺がん患者の予後予測方法、内部標準、抗体、肺がん患者の予後予測装置、予後予測装置のプログラム及び記録媒体
JP2018512160A (ja) * 2015-04-14 2018-05-17 ジーンセントリック セラピューティクス， インコーポレイテッド 肺がんのタイピングのための方法
CA2997674A1 (en) * 2015-09-09 2017-03-16 Theoria Science Inc. Exosome secretion inhibitor
WO2017061522A1 (ja) 2015-10-08 2017-04-13 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１由来ペプチドおよびそれを含むワクチン
KR20180056778A (ko) 2015-10-08 2018-05-29 온코세라피 사이언스 가부시키가이샤 Foxm1 유래 펩티드 및 이를 포함하는 백신
EP3458611B1 (de) 2016-05-17 2023-11-08 Genecentric Therapeutics, Inc. Verfahren zur subtypisierung von plattenzellkarzinomen
CA3024747A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
BR112019003408A2 (pt) 2016-08-31 2019-06-25 Oncotherapy Science Inc anticorpo monoclonal contra a melk e utilização da mesma
TWI762516B (zh) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 針對ｆｚｄ１０之單株抗體及其用途
NL2020004B1 (en) 2016-12-09 2018-07-02 Ary Flohil Jacob Treatment of diffuse intrinsic pontine glioma
MY192920A (en) * 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
EP3607089A4 (de) 2017-04-04 2020-12-30 Lung Cancer Proteomics, LLC Plasmabasierte proteinprofilierung für lungenkrebsprognose im frühstadium
US11735108B2 (en) 2019-07-31 2023-08-22 Boe Technology Group Co., Ltd. Display substrate and preparation method thereof, display panel, and display device
KR20220157009A (ko) 2021-05-20 2022-11-29 한국식품연구원 구강미생물 정보를 이용한 폐암의 조기진단 및 위험성 예측 방법 또는 이를 위한 조성물
CN113925877B (zh) * 2021-10-28 2022-06-07 青岛西凯生物技术有限公司 基因增强型免疫细胞在肺癌中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (de) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Verfahren zur Herstellung eines Human-Human-Hybridoms
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0546073B1 (de) 1990-08-29 1997-09-10 GenPharm International, Inc. Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
GB9114005D0 (en) 1991-06-28 1991-08-14 Automotive Prod Plc A clutch control system
WO1993002227A1 (en) 1991-07-15 1993-02-04 Eco-Tec Limited Process and apparatus for treating fluoride containing acid solutions
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5403494A (en) 1993-07-15 1995-04-04 The Lawrence Paper Company Method of recovery of single color printing ink wastes
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1999038972A2 (en) * 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii
AU4187499A (en) * 1998-05-14 1999-11-29 Chiron Corporation Human genes and gene expression products v
US20020103360A1 (en) 1998-09-01 2002-08-01 Yang Pan Novel protein related to melanoma-inhibiting protein and uses thereof
EP1130094A3 (de) * 1999-07-08 2001-11-21 Helix Research Institute Primer zur Synthese von vollständigen cDNA Klonen und ihre Verwendung
ATE420175T1 (de) * 1999-08-12 2009-01-15 Agensys Inc C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001287269A1 (en) * 2000-03-28 2001-10-08 Chiron Corporation Human genes and expression products
WO2001072775A2 (en) * 2000-03-29 2001-10-04 Diadexus, Inc. Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US6974667B2 (en) * 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
JP2004512824A (ja) * 2000-07-11 2004-04-30 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US20070015148A1 (en) * 2001-01-25 2007-01-18 Orr Michael S Gene expression profiles in breast tissue
JP4429604B2 (ja) * 2001-02-21 2010-03-10 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 診断におけるｔｔｋおよび癌における治療標的としてのｔｔｋ
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
EP2336778A1 (de) * 2004-03-24 2011-06-22 Oncotherapy Science, Inc. Zusammensetzungen und Verfahren zur Behandlung von Lungenkrebs
DE602006021283D1 (de) * 2005-02-25 2011-05-26 Oncotherapy Science Inc Peptid-impfstoff für lungenkrebs, der ttk polypeptide exprimiert
EP2423332A1 (de) * 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognosemarker und therapeutische Targets für Lungenkrebs
BRPI0815769A2 (pt) * 2007-08-24 2017-08-08 Oncotherapy Science Inc Ebi3, dlx5, nptx1 e cdkn3 como genes alvo da terapia e diagnóstico de câncer de pulmão

Also Published As

Publication number Publication date
EP2270503A3 (de) 2011-01-19
EP2270500A1 (de) 2011-01-05
EP1551998A2 (de) 2005-07-13
EP2270215A3 (de) 2011-07-20
EP2264186A1 (de) 2010-12-22
EP2270502A2 (de) 2011-01-05
EP2270218A2 (de) 2011-01-05
TW200413725A (en) 2004-08-01
EP1743947A3 (de) 2007-05-23
EP2264187A1 (de) 2010-12-22
EP2270217A2 (de) 2011-01-05
KR101075158B1 (ko) 2011-10-19
EP1743947B1 (de) 2012-01-11
EP2270214A3 (de) 2011-07-20
EP2270210A3 (de) 2011-06-22
EP2270213A3 (de) 2011-06-29
EP2270211A2 (de) 2011-01-05
EP2270219A2 (de) 2011-01-05
EP2270220A2 (de) 2011-01-05
EP2270210A2 (de) 2011-01-05
EP2270498A2 (de) 2011-01-05
JP2012125247A (ja) 2012-07-05
EP2270501A3 (de) 2011-01-19
EP2264185A1 (de) 2010-12-22
EP2270224A3 (de) 2011-10-05
KR20110020953A (ko) 2011-03-03
EP2270219A3 (de) 2011-07-27
EP2270222A2 (de) 2011-01-05
CA2500151A1 (en) 2004-04-15
WO2004031413A2 (en) 2004-04-15
EP2270221A2 (de) 2011-01-05
JP4425141B2 (ja) 2010-03-03
EP2270217A3 (de) 2011-07-27
EP2270498A3 (de) 2011-02-02
AU2003272088A1 (en) 2004-04-23
EP2270499A1 (de) 2011-01-05
JP4921522B2 (ja) 2012-04-25
EP2270211A3 (de) 2011-06-22
EP2270220A3 (de) 2011-09-28
EP2270502A3 (de) 2011-01-26
KR20050074468A (ko) 2005-07-18
JP2009240313A (ja) 2009-10-22
EP2270221A3 (de) 2011-09-28
EP1743947A2 (de) 2007-01-17
EP2270225A3 (de) 2011-10-05
EP2270225A2 (de) 2011-01-05
EP2270503A2 (de) 2011-01-05
EP2270501A2 (de) 2011-01-05
EP2270224A2 (de) 2011-01-05
EP2270213A2 (de) 2011-01-05
EP2264457A1 (de) 2010-12-22
EP2270215A2 (de) 2011-01-05
EP2270223A2 (de) 2011-01-05
EP2264190A1 (de) 2010-12-22
AU2003272088A8 (en) 2004-04-23
WO2004031413A9 (en) 2005-08-04
EP2270214A2 (de) 2011-01-05
EP2270216A2 (de) 2011-01-05
EP2270212A2 (de) 2011-01-05
JP2010042016A (ja) 2010-02-25
WO2004031413A3 (en) 2005-02-24
EP2270212A3 (de) 2011-06-29
EP2270216A3 (de) 2011-07-20
EP2278028A1 (de) 2011-01-26
JP2006500949A (ja) 2006-01-12

Similar Documents

Publication Publication Date Title
ATE541053T1 (de) Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs
ATE519862T1 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
ATE511503T1 (de) Aryl- und heteroarylharnstoff-chk1-inhibitoren zur verwendung als radiosensibilisatoren und chemosensibilisatoren
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
DE602004015064D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
ATE522623T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DE69911210D1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE397003T1 (de) Ruthenium(ii)-komplexe zur behandlung von tumoren
DE502004009491D1 (de) Thiaepothilone zur behandlung von krebserkrankungen
ATE411313T1 (de) Neue makrocyclen zur behandlung von krebserkrankungen